Inventor · disambiguated record
George Coukos
Also filed as: COUKOS GEORGE
15 granted patents·20 pending applications·65 citations·filing 2003–2023
89Inventor score
Files withLUDWIG INST FOR CANCER RES LTD9UNIV PENNSYLVANIA8NESTLE SA5COUKOS GEORGE4SIB SWISS INST OF BIOINFORMATICS2
Top patents by PatentIndex Score
35 records- 0193US9402865B2Compositions and methods for treating cancerPOWELL DANIEL J·Filed 2012·Granted Aug 2, 2016·53 cites·34 claims
- 0282US10457729B2Compositions and methods for treating cancerUNIV PENNSYLVANIA·Filed 2016·Granted Oct 29, 2019·3 cites·30 claims
- 0382US10160809B2Anti-TEM1 antibodies and uses thereofUNIV PENNSYLVANIA·Filed 2017·Granted Dec 25, 2018·3 cites·5 claims
- 0481US10174120B2Methods and compositions for treating solid tumors and enhancing tumor vaccinesUNIV PENNSYLVANIA·Filed 2016·Granted Jan 8, 2019·4 cites·2 claims
- 0575US11180550B2Compositions and methods for treating cancerUNIV PENNSYLVANIA·Filed 2019·Granted Nov 23, 2021·0 cites·22 claims
- 0674US10874728B2Tumor vascular marker-targeted vaccinesUNIV PENNSYLVANIA·Filed 2016·Granted Dec 29, 2020·1 cites·3 claims
- 0772US12478626B2Kinase mutants and uses thereofSIB SWISS INST OF BIOINFORMATICS·Filed 2023·Granted Nov 25, 2025·0 cites·15 claims
- 0872US2022324963A1Compositions and methods for treating cancerTHE TRUSTEES OF THE UNIVERITY OF PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 0967US9556272B2Anti-TEM1 antibodies and uses thereofSCHOLLER NATHALIE·Filed 2010·Granted Jan 31, 2017·1 cites·18 claims
- 1066US11078285B2Anti-TEM1 antibodies and uses thereofUNIV PENNSYLVANIA·Filed 2018·Granted Aug 3, 2021·0 cites·5 claims
- 1166US9290556B2Tumor vascular marker-targeted vaccinesCOUKOS GEORGE·Filed 2009·Granted Mar 22, 2016·0 cites·5 claims
- 1261US2025032447A1Use of urolithin in the remission phase of a preceding cancer therapyNESTLE SA·Filed 2023·Application pending·0 cites
- 1358US2024010981A1Compositions and methods for increasing stem cell functionNESTLE SA·Filed 2021·Application pending·0 cites
- 1457US11738049B2Kinase mutants and uses thereofSIB SWISS INST OF BIOINFORMATICS·Filed 2018·Granted Aug 29, 2023·0 cites·6 claims
- 1557US2024327491A1T cell receptors specific for tumor-associated antigens and methods of use thereofLUDWIG INST FOR CANCER RES LTD·Filed 2022·Application pending·0 cites
- 1656US2024287454A1Single vessel expansion of lymphocytesTIGEN PHARMA SA·Filed 2022·Application pending·0 cites
- 1755US2023365933A1Compositions and methods for increasing stem cell functionNESTLE SA·Filed 2021·Application pending·0 cites
- 1855US2025009802A1Antisense transfer vectors and methods of use thereofLUDWIG INST FOR CANCER RES LTD·Filed 2022·Application pending·0 cites
- 1954US12473346B2A2/NY-ESO-1 specific t cell receptors and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Nov 18, 2025·0 cites·22 claims
- 2054US2019375845A1Methods and compositions for treating solid tumors and enhancing tumor vaccinesUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
- 2153US9289426B2Methods and compositions for treating solid tumors and enhancing tumor vaccinesBUCKANOVICH RONALD J·Filed 2008·Granted Mar 22, 2016·0 cites·12 claims
- 2253US2023414660A1Pd-1 decoy variants for immunotherapyLUDWIG INST FOR CANCER RES LTD·Filed 2021·Application pending·0 cites
- 2351US2009047216A1Tumor vasculature markers and methods of use thereofCOUKOS GEORGE·Filed 2007·Application pending·0 cites
- 2451US2009274619A1Tumor vasculature markers and methods of use therofCOUKOS GEORGE·Filed 2007·Application pending·0 cites
- 2551US2024207319A1Compositions and methods for immunotherapyLUDWIG INST FOR CANCER RES LTD·Filed 2022·Application pending·0 cites
- 2649US2022241240A1Agents and methods for increasing stem cell functionNESTLE SA·Filed 2020·Application pending·0 cites
- 2748US2022387555A1Compositions and methods for immunotherapyLUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 2847US2020338125A1Method for expansion of lymphocytesLUDWIG INST FOR CANCER RES LTD·Filed 2018·Application pending·0 cites
- 2947US2023141511A1Car-t cell therapy targeting ngcgm3LUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 3045US12297276B2Anti-TEM1 antibodies and antigen-binding portions thereofLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted May 13, 2025·0 cites·32 claims
- 3145US9783610B2Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereofUNIV PENNSYLVANIA·Filed 2013·Granted Oct 10, 2017·0 cites·4 claims
- 3245US2022168271A1Compositions and methods for increasing t cell functionNESTLE SA·Filed 2020·Application pending·0 cites
- 3343US2006247420A1Immune cell recptor ligand and immune cell receptorCOUKOS GEORGE·Filed 2003·Application pending·0 cites
- 3442US2012219615A1Therapeutic Use of a TLR Agonist and Combination TherapyHERSHBERG ROBERT·Filed 2011·Application pending·0 cites
- 3541US2022152107A1Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapiesCT INMUNOLOGIA MOLECULAR·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when George Coukos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →